ZYUS Life Sciences Corporation ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -34.20% | 87.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -34.20% | 87.95% | |||
| Cost of Revenue | -22.95% | -66.64% | |||
| Gross Profit | -47.63% | 140.51% | |||
| SG&A Expenses | -4.28% | 4.46% | |||
| Depreciation & Amortization | -6.03% | -72.14% | |||
| Other Operating Expenses | -34.09% | -91.93% | |||
| Total Operating Expenses | -5.48% | -36.86% | |||
| Operating Income | 3.96% | 39.01% | |||
| Income Before Tax | 1.38% | 68.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.38% | 68.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.38% | 68.00% | |||
| EBIT | 3.96% | 39.01% | |||
| EBITDA | 3.79% | 40.20% | |||
| EPS Basic | 2.15% | 68.30% | |||
| Normalized Basic EPS | 1.72% | 41.41% | |||
| EPS Diluted | 1.03% | 66.82% | |||
| Normalized Diluted EPS | 1.72% | 41.41% | |||
| Average Basic Shares Outstanding | 0.49% | 1.04% | |||
| Average Diluted Shares Outstanding | 0.49% | 1.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||